1
Country: Israel | Funding: $1B
Novocure is developing a new treatment for solid tumors known as tumor polytherapy (TTFields). TTFields are low-intensity alternating electric fields, particularly at intermediate frequencies that disrupt cancer cell division through physical interaction with key molecules during mitosis. TTFields do significantly affect healthy cells, as they have different properties (including division rate, morphology and electrical properties) compared to cancer cells. The company's TTFields pipeline includes therapies against glioblastoma, metastatic non-small cell lung cancer and pancreatic cancer. The company also produces FDA-approved portable devices for the treatment of GB and mNSCLC. These devices also work via creating electric fields that can slow or stop cancer cell division.
Novocure is developing a new treatment for solid tumors known as tumor polytherapy (TTFields). TTFields are low-intensity alternating electric fields, particularly at intermediate frequencies that disrupt cancer cell division through physical interaction with key molecules during mitosis. TTFields do significantly affect healthy cells, as they have different properties (including division rate, morphology and electrical properties) compared to cancer cells. The company's TTFields pipeline includes therapies against glioblastoma, metastatic non-small cell lung cancer and pancreatic cancer. The company also produces FDA-approved portable devices for the treatment of GB and mNSCLC. These devices also work via creating electric fields that can slow or stop cancer cell division.
2
Country: USA | Funding: $253.7M
Imvax develops personalized immunotherapeutic cancer vaccines against glioblastoma and other solid tumors that are created from the patient's own tumor cells. Imvax's Goldspire platform delivers a combo of patient-derived tumor cells and an antisense oligodeoxynucleotide (IMV-001) against the insulin-like growth factor receptor type 1 (IGF-1R). This combination is loaded into implantable, proprietary biodiffusion chambers. This technology is designed to provide both innate and adaptive immune stimulation to overcome the challenges associated with the variability of solid tumors and their ability to suppress the immune system. Imvax is developing a diverse portfolio of drugs against glioblastoma, endometrial cancer, hepatocellular carcinoma, urothelial cancer and ovarian cancer.
Imvax develops personalized immunotherapeutic cancer vaccines against glioblastoma and other solid tumors that are created from the patient's own tumor cells. Imvax's Goldspire platform delivers a combo of patient-derived tumor cells and an antisense oligodeoxynucleotide (IMV-001) against the insulin-like growth factor receptor type 1 (IGF-1R). This combination is loaded into implantable, proprietary biodiffusion chambers. This technology is designed to provide both innate and adaptive immune stimulation to overcome the challenges associated with the variability of solid tumors and their ability to suppress the immune system. Imvax is developing a diverse portfolio of drugs against glioblastoma, endometrial cancer, hepatocellular carcinoma, urothelial cancer and ovarian cancer.
3
Country: Denmark | Funding: $249.6M
ADCendo develops antibody-drug conjugates (ADCs) for the treatment of cancers with high unmet medical needs. The company is developing two technologies: ADCE-T02, which combines an optimized monoclonal antibody targeting tissue factor (overexpressed in numerous solid tumor indications) with a next-generation linker and exatecan delivery technology, providing higher efficacy and improved tolerability. The second candidate is ADCE-D01 - a first-in-class ADC targeting uPARAP, an endocytic receptor overexpressed in a wide range of mesenchymal tumors, including soft tissue sarcomas, osteosarcoma, GISTs, mesothelioma and glioblastoma.
ADCendo develops antibody-drug conjugates (ADCs) for the treatment of cancers with high unmet medical needs. The company is developing two technologies: ADCE-T02, which combines an optimized monoclonal antibody targeting tissue factor (overexpressed in numerous solid tumor indications) with a next-generation linker and exatecan delivery technology, providing higher efficacy and improved tolerability. The second candidate is ADCE-D01 - a first-in-class ADC targeting uPARAP, an endocytic receptor overexpressed in a wide range of mesenchymal tumors, including soft tissue sarcomas, osteosarcoma, GISTs, mesothelioma and glioblastoma.
4
Country: UK | Funding: $6.8M
QV Bioelectronics has developed GRACE - implant for the treatment of brain tumors (with an initial focus on glioblastoma). The device is installed during surgery and delivers continuous, precisely targeted electrical fields that disrupt dividing tumor cells, destroying cancer without damaging healthy tissue. This is achieved by focusing the field only on the affected area of the brain. The implantation requires a minimal number of external devices, allowing patients to remain active, independent, and connected to their favorite activities. Now the company is preparing first-in-human trial of GRACE
QV Bioelectronics has developed GRACE - implant for the treatment of brain tumors (with an initial focus on glioblastoma). The device is installed during surgery and delivers continuous, precisely targeted electrical fields that disrupt dividing tumor cells, destroying cancer without damaging healthy tissue. This is achieved by focusing the field only on the affected area of the brain. The implantation requires a minimal number of external devices, allowing patients to remain active, independent, and connected to their favorite activities. Now the company is preparing first-in-human trial of GRACE
5
Country: USA | Funding: $3.5M
OX2 Therapeutics is developing immunotherapy for the treatment of brain tumors based on scientific discoveries of the University of Minnesota. OX2 Therapeutics has developed a first-of-its-kind peptide that targets the immune checkpoint activation receptor CD200. The peptide activates the immune system through a mechanism that modulates the suppressive effects of the immune checkpoints CD200, PD-1/PD-L1 and CTLA4, enabling more potent antitumor response. CD200 is upregulated on tumor-associated vascular endothelial cells, creating an immunological barrier that inactivates T cells (cancer-fighting cells) as they attempt to penetrate the tumor environment. The company has received FDA clearance to conduct clinical trials of combination therapy for the treatment of high-grade glioblastoma, for which there is no curative therapy.
OX2 Therapeutics is developing immunotherapy for the treatment of brain tumors based on scientific discoveries of the University of Minnesota. OX2 Therapeutics has developed a first-of-its-kind peptide that targets the immune checkpoint activation receptor CD200. The peptide activates the immune system through a mechanism that modulates the suppressive effects of the immune checkpoints CD200, PD-1/PD-L1 and CTLA4, enabling more potent antitumor response. CD200 is upregulated on tumor-associated vascular endothelial cells, creating an immunological barrier that inactivates T cells (cancer-fighting cells) as they attempt to penetrate the tumor environment. The company has received FDA clearance to conduct clinical trials of combination therapy for the treatment of high-grade glioblastoma, for which there is no curative therapy.
6
Country: Sweden | Funding: €71.4K
Our mission is to bring value to every patient by maximizing the capacity of some of the most effective medicines known and make them even better. Our areas of expertise are brain cancer, liver cancer and pneumonia. We have developed ways to treat these diseases much more effectively with our drug delivery system.
Our mission is to bring value to every patient by maximizing the capacity of some of the most effective medicines known and make them even better. Our areas of expertise are brain cancer, liver cancer and pneumonia. We have developed ways to treat these diseases much more effectively with our drug delivery system.
